Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study

Digestion - Switzerland
doi 10.1159/000445187
Full Text
Abstract

Available in full text

Date
Authors
Publisher

S. Karger AG

Related search

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

A Phase II Trial of Fixed-Dose Rate Gemcitabine Plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

Oncology
MedicineCancer ResearchOncology
2012English

Efficacy of Fluoropyrimidine-Based Chemotherapy in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin: Retrospective Analysis of 321 Patients

British Journal of Cancer
Cancer ResearchOncology
2017English

A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Adenocarcinomas

British Journal of Cancer
Cancer ResearchOncology
2013English

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression After First-Line Gemcitabine Plus Cisplatin

Cancer Research and Treatment
Cancer ResearchOncology
2019English

A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

A Case of Advanced Biliary Tract Cancer Successfully Treated With Single-Agent Gemcitabine Chemotherapy in Combination With Juzentaihoto

Kampo Medicine
2012English

EGFR and HER2 Expression in Advanced Biliary Tract Cancer

Zeitschrift fur Gastroenterologie
MedicineGastroenterology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy